Evaluate the Effect of Atorvastatin on the Pharmacokinetics of Lomitapide in Healthy Subjects.
Status:
Completed
Trial end date:
2014-03-07
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess the effect of atorvastatin, a weak
cytochrome P450 (CYP) 3A4 inhibitor, on the pharmacokinetics (PK) of lomitapide and its 2
primary metabolites, M1 and M3.